Buy the full study
Summary of our market study
The European insulin pump market is worth around 2.4 billion.
The global insulin pump market, valued at $5.67 billion in 2022, is expected to grow at a CAGR of 8.8%, reaching $9.4 billion by 2028.
Driven by a sharp rise in diabetes worldwide, particularly in regions such as Africa, Asia-Pacific and the Middle East, this market is experiencing significant growth.In 2021 alone, the global diabetes population grew by 74 million to 537 million, with forecasts of 643 million by 2030 and 783 million by 2045. In Asia-Pacific, the Middle East, North Africa and Africa, the diabetic population could more than double by 2045 compared with 2021.
The French market, with an average annual growth rate of 6.58%, and spending such as the 9.6 billion euros allocated to diabetes care by the French health insurance system in 2021, reflect the robust dynamics of this sector. Innovations and the introduction of advanced insulin pump models, such as Medtronic's Minimed 780G, Omnipod DASH and Tandem's t:slim X2, meet the needs of an increasingly aware diabetic population.
Major entities such as Medtronic, Roche and others are dominating the scene, focusing on connected technologies and more patient-friendly solutions to improve diabetes management.
Insulin pump market trends and dynamics in France
The French insulin pump market is set to grow at a CAGR of around 6-7% between 2023 and 2028.
France faces major challenges in diabetes care, with around 3 to 4 million people being treated, and an alarming estimate that almost a million French citizens are undiagnosed. Despite a slight drop in 2020, the number of people receiving care has again risen substantially, reaching over 4 million in 2021.
Type 2 diabetes dominates the landscape, accounting for 92% of cases, with type 1 and rarer forms making up the remainder. Those most affected are the over-65s, who account for over 60% of the diabetic population, with men slightly outnumbering women in terms of prevalence.
Regions such as Hauts-de-France and Grand-Est have higher prevalence rates than the national average. Diabetes also coincides with comorbidities such as cardiovascular disease, psychotropic medication use, cancer and chronic respiratory conditions.
A significant trend in insulin pump use in France indicates that while almost 860,000 people are on insulin therapy, only 2-5% of diabetics use insulin pump technology, compared with 25% in the USA.
However, this landscape is changing with the steady increase in insulin pump adoption among French diabetics. The number of users has increased almost fourfold to 82,000.
Market expansion is also being driven by health insurance reimbursements, which play a central role in the accessibility of these devices. Such growth indicates an increasing trend in pump use, further amplified by the inclusion of new models such as the Minimed™ 780G, Omnipod DASH™.
Key manufacturers dominating the insulin pump landscape
- Medtronic Medtronic is a pioneer in insulin pumps. abète.
- Roche is a pillar of the insulin pump market under the banner of its Accu-Chek brand,
- Medtronic and Abbott
- Insulet is renowned for its revolutionary Omnipod device,
- Ypsomed has made its mark on the market with the myLife Ypsopump
- Cellnovo Smaller player
to understand this market
Detailed content of our market study
Inforamtion
- Number of pages : ~ 40 pages
- Format : Digital and PDF versions
- Last update :
Summary and extracts
1 Market overview
1.1 Insulin pump market overview and definition
The insulin pump is a treatment method for diabetics. It is an an interesting alternative to multi-injection therapy insulin injections, helping to maintain better glycemic control. Mimicking the functioning of a normal pancreas, it is an artificial device that delivers insulin at a variable rate to an insulin-dependent diabetic requiring insulin on a permanent basis.
Theinsulin pump can be implanted (rarely prescribed by physicians) or external (subcutaneous injection) . Operation is straightforward, with in-hospital training and regular follow-up with the diabetologist and pump vendor.
The global insulin market is growing, dominated by a handful of very powerful laboratories offering insulin pens and oral medications. Insulin pump sales constitute one segment of the insulin treatment market.
The insulin pump market segment is also growing, and is set to remain so for years to come, driven by the various innovations proposed by traditional and emerging players. This global market is estimated atUS$5.67 billion in 2022, andshould reach US$9.4 billion in 2028 (at aCAGR of 8.8%). [GrandViewResearch]
Indeed, in 2021, there will now be 537 million diabetics in the world, 3.5 times more than in 2000. Between 2019 and 2021, for example, the number of diabetics rose by 74 million. To date, Asia-Pacific has the highest number of people with diabetes (206 million), but the increase is expected to beparticularly strong in Africa (+134% in 2045 compared with 2021) [DiabetesAtlas]
France is one of Europe's biggest consumers of diabetes treatments, with healthcare expenditure linked to this disease amounting to over 22 billion euros in 2021[DiabetesAtlas]. As a result, the insulin pump market is highly dynamic, and is expected to grow at a CAGR of 6.58% over the period 2023-2028. [Mordor Intelligence]
The market for diabetes treatment is very closely linked to the regulations and healthcare system in place. For example, the French social security system allows insulin pump treatment to be reimbursed, and regularly updates the new pumps that are eligible for reimbursement.
1.2 The global market
The global insulin pump market is estimated at US$*.** billion in ****, and is expected to continue growing over the next few years at a CAGR of *.*%, reaching US$*.* billion in ****.
Insulin pump market size World, **** - ****, in billions of USD Source: GandViewResearch (***) : projection
Global market growth drivers include the rising number ...
1.3 Growth in the French market
The following graph shows the evolution of diabetes-related healthcare expenditure in France. This figure includes all diabetes-related expenses in France. It includes, for example, all the costs of insulin therapy, visits to healthcare professionals and equipment, as well as all the resources devoted to prevention, nutrition and so on. It also ...
2 Demand analysis
2.1 The profile of diabetes patients
The number of diabetics under care is trending upwards in France, rising from *.* million in **** to * million in ****, an increase of **% in just * years. However, by ****, the number of people in care would have fallen by ***,***, before rising again by ***,*** in ****, to around *.* million.
People treated for diabetes in **** (***) France, **** - ...
2.2 Obesity and overweight as risk factors
Obesity and diabetes are two closely related diseases. In fact, according to the Pasteur Institute in Lille, obesity is the leading risk factor for diabetes, and **% of obese people also suffer from diabetes. The increase in obesity and overweight is the main reason for the sharp rise in the number of ...
2.3 Insulin pump users among diabetics
Of the *,***,*** diabetic patients who were treated in ****, (***).
According to Has-Santé, the population of French patients using external insulin pumps stood at **,*** in ****. This would mean that only *% of diabetics would be using this device. According to lvlmedical, however, *% of diabetics will be using an insulin pump. by way of comparison, ...
3 Market structure
3.1 The central role of health insurance and reimbursements
The French Assurance Maladie plays a central role in the insulin pump market, as it does for many drugs, treatments and medical equipment. As diabetes is classified as a long-term condition (***), costs are ***% covered by the French health insurance system, whether for diabetes-related care or for complications: ocular, vascular, renal or ...
3.2 The main players in the diabetes treatments market
The global market for anti-diabetic treatments is not very fragmented, and is dominated by a handful of large international groups. Evaluate Pharma provides annual reports on the global pharmaceutical market, but only the **** report focuses on the anti-diabetic market.
In ****, the top ** groups accounted for over **% of total market value, including ...
3.3 Leading insulin pump manufacturers
The French insulin pump market is highly fragmented and dominated by a handful of industry giants .
Medtronic
Sales of the Medtronic group's Diabetes division have grown steadily in recent years, from $*.** billion in **** to $*.** billion in ****. A world leader in medical technologies, the group has a very strong presence in the ...
4 Offer analysis
4.1 Insulin pump typology
Insulin pumps are medical devices used in the treatment of diabetes (***). Compared with multi-injection therapy, the insulin pump enables patients to maintain a freer, more flexible lifestyle, with greater flexibility in mealtimes, as well as better monitoring of blood glucose levels, and therefore a lower risk of complications.
The insulin pump ...
4.2 Product innovation on the market
Digital technology in diabetes treatment
Manufacturers in the insulin therapy market are increasingly investing in the connected objects segment to meet consumer expectations. For example, Abbott and Sanofi, as well as Medtronic and Novo Nordisk, have signed alliances in **** to advance in the connected pen segment.
In particular, Abbott has launched ...
5 Regulations
5.1 Supervision of insulin pump therapy
Prescriptions[***]
Insulin pumps are reimbursed by the French national health insurance scheme (***) for type * and type * diabetes which cannot be controlledby insulin therapy using multiple subcutaneous injections of insulin.
The initial prescription for an external insulin pump (***) must be made in an initiating center. This prescription is valid for a maximum ...
6 Positioning the players
6. Segmentation
- Medtronic
- Cellnovo
- Roche Diabetes Care (Roche Groupe)
- Insulet
- Ypsomed Group
- ISIS diabète (Isis Médical)
- Physidia
- Nova Medical Center
- Medtrum
- Apex Wellell
- Open APS
- Eli Lilly
- TreeFrog Therapeutics
- Boydsense
List of charts presented in this market study
- Insulin pump market size
- Distribution of the number of diabetics by world region
- Distribution of diabetics by world region
- Growth in the number of diabetics worldwide
- Countries with the highest number of diabetics
All our studies are available online in PDF format
Take a look at an example of our research on another market!
Latest news
Physidia, the home dialysis specialist, goes British - 13/06/2023
- Physidia is an SME based in Angers specializing in home hemodialysis.
- Founded in 2010 in Angers.
- The company has developed a machine called S3, which enables patients to carry out their daily dialysis independently at home.
- Physidia has around 60 employees.
- Annual growth rate of 45.12% between 2018 and 2021.
- Sales of €22 million in the last financial year
- Physidia distributes its home dialysis solutions in 16 countries in Europe and the Middle East.
Eli Lilly has become the world's largest pharmaceutical company - 08/06/2023
- Eli Lilly market capitalization: $408 billion
- Obesity market estimate for 2030: $100 billion.
- Obesity market estimate for 2022: $4 billion.
- Number of people suffering from Alzheimer's disease worldwide: 55 million.
- Number of Alzheimer's sufferers in Europe: 10 million.
- Estimated Alzheimer's disease market in 2020: 30 billion euros.
ISIS Diabète: The specialist in home assistance for diabetes. - 29/05/2023
- ISIS DIABÈTE is the third largest player in its market in France.
- The company is an expert in the care and support of people with diabetes at home.
- They offer services such as training and technical expertise in insulin pumps, glucose sensors, automated insulin delivery algorithms (closed loop) and associated digital platforms.
- ISIS DIABÈTE has set up a tele-monitoring service called TÉLÉSIS, dedicated to people with diabetes, the only one of its kind in France.
- The company is ISO 9001 certified and has been awarded the Qualipsad label, dedicated to players in the field of home healthcare services.
- 98% of patients who use ISIS DIABÈTE services are fully satisfied with the support they receive, according to the company's latest survey.
Companies quoted in this study
This study contains a complete overview of the companies in the market, with the latest figures and news for each company. :
Choosing this study means :
Access to more than 35 hours of work
Our studies are the result of over 35 hours of research and analysis. Using our studies allows you to devote more time and added value to your projects.
Benefit from 6 years' experience and over 1,500 industry reports already produced
Our expertise enables us to produce comprehensive studies in all sectors, including niche and emerging markets.
Our know-how and methodology enable us to produce reports that offer unique value for money.
Access to several thousand articles and paid-for data
Businesscoot has access to all the paid economic press as well as exclusive databases to carry out its market research (over 30,000 articles and private sources).
To enhance our research, our analysts also use web indicators (semrush, trends, etc.) to identify market trends and company strategies. (Consult our paying sources)
Guaranteed support after your purchase
A team dedicated to after-sales service, to guarantee you a high level of satisfaction. +44 238 097 0676
A digital format designed for our users
Not only do you have access to a PDF, but also to a digital version designed for our customers. This version gives you access to sources, data in Excel format and graphics. The content of the study can therefore be easily retrieved and adapted for your specific needs.
Our offers :
the Insulin Pump Market | France
- What are the figures on the size and growth of the market?
- What is driving the growth of the market and its evolution?
- What is the positioning of companies in the value chain?
- Data from several dozen databases
Pack 5 études (-15%) France
- 5 études au prix de 75,6€HT par étude à choisir parmi nos 800 titres sur le catalogue France pendant 12 mois
- Conservez -15% sur les études supplémentaires achetées
- Choisissez le remboursement des crédits non consommés au terme des 12 mois (durée du pack)
Consultez les conditions du pack et de remboursement des crédits non consommés.
Our customer references
They have consulted our studies
Discover the opinions (+500)
Malcolm Vincent
Astoria Finance
Gregoire de Castelnau
Stags Participations
Timothé Huignard
PWC
Paul-Alexis Kebabtchieff
BCG
Aymeric Granet
Publicis Consultant
interviews & case studies
All interviews and case studies (45)
